Clinical trial

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

NCT04606446

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2020-11-16

PhasePHASE2

Study timeline

Study start (actual)2020-11-16Date precision: day

Registry last updated2026-04-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Locally Advanced or Metastatic ER+ HER2- Breast Cancerunresolved

Locally Advanced or Metastatic Castration-resistant Prostate Cancerunresolved

Locally Advanced or Metastatic Non-small Cell Lung Cancerunresolved

Interventions

PF-07248144DRUG

FulvestrantDRUG · verified · RxNorm: fulvestrant

LetrozoleDRUG · verified · RxNorm: letrozole

PalbociclibDRUG · verified · RxNorm: palbociclib

PF-07220060DRUG

PF-07850327, ARV-471, vepdegestrantDRUG

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

New HavenConnecticut, United States4 HoustonTexas, United States3 LouisvilleKentucky, United States3 Los AngelesCalifornia, United States2 SeattleWashington, United States2 ChangchunJilin, China2 San AntonioTexas, United States1 NashvilleTennessee, United States1 SeoulSouth Korea1 San FranciscoCalifornia, United States1 BeijingBeijing Municipality, China1 GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04606446 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.